to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
In Part Two of our look at early-stage entrepreneurial funding, we examine the pros and cons of the two primary startup funding mechanisms: venture capital and angel funding.
As year-end approaches and entrepreneurs regroup to figure out financing options for 2012, it's a good time to take a look at the two major sources of new business funding -- angel investing versus venture capital.
The number of life sciences venture deals was down in the third quarter and first-time funding was down as well. Read more about the reasons behind the numbers.
Venture firms are approaching angel investor groups to co-invest at the growth stage of startups. Read more about the impact this could have on startup health IT companies.
Medical foundations play a role in helping medicine advance through their philanthropy, but sometimes even the most well-intentioned of them can lose their way. Read more about how these foundations can stay focused on their goals.
Can "boom and bust" cycles exist in the venture funding market? You bet they can. And recent data from the chemical sector is a great example of how and why.
In a venture funding climate seeking large returns, thousands of potentially successful entrepreneurial startups can't get the financing they need to make a difference in the economy and in the culture. The problem isn't a new one, but it is a damaging one.
The number of healthcare venture deals is at its lowest level in at least five quarters, according to a new report. However, healthcare seed investment hit a record high in the same quarter.
There's stability and then there's outright growth. For healthcare business owners looking for angel funding, they'll have to accept the former and wait some more on the latter. But at least it's progress.
Regenerative medicine has come a long way in recent years, leading some venture capitalists to consider investing in it. The roadblock to investing in this field is not a lack of funds, but rather a lack of a clear explanation of regenerative medicine's commercial applications, says one former venture capitalist.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.